Expert Perspectives on the Current Role of CAR-T Cell Therapy in Patients with Mantle Cell Lymphoma (MCL)

In an interview with Targeted Oncology, Julie Chang, MD, discussed the minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma and the key findings from the trial.

Technology plays a pivotal role in enhancing precision medicine within cancer care.

Improving patient prognostication in mantle cell lymphoma informs treatment decisions and enhances our understanding of the disease's biology.

Findings suggest that liso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features, who have limited treatment options.

In the fifth article of this series, Yazan Madanat, MD, reviews recent updates presented at the 2023 ASH Annual Meeting and discusses the evolving treatment landscape.

Matthew Matasar, MD, discussed the rationale and findings of the doublet consisting of ibrutinib and venetoclax for the treatment of mantle cell lymphoma.